Purification of Urokinase from Complex Mixtures Using Immobilized Monoclonal Antibody Against Urokinase Light Chain

Summary

The preparation of a monoclonal antibody (MAB) against high molecular weight (HMW) urokinase light chain (20,000 M_r) is described. This MAB was immobilized and the resulting immunosorbent was used to isolate urokinase starting with an impure commercial preparation, fresh urine, spent tissue culture media, or E. coli broth without preliminary dialysis or concentration steps. Monospecific antibodies appear to provide a rapid single step method of purifying urokinase, in high yield, from a variety of biological fluids.

Keywords

Monoclonal antibody - Urokinase - Purification - Complex mixtures

• References

• 1 Ong EB, Soberano ME, Johnson AJ, Dharmsronsartama ED. The plasminogen activator and esterase activities of the two forms of urokinase. Thromb Res 1981; 24: 223-232
• 2 McLellan WL, Vetterlein D, Roblin R. The glycoprotein nature of human plasminogen activators. FEBS Letters 1980; 115: 181-184
• 3 Soberano ME, Ong EB, Johnson AJ. The effects of inhibitors on the catalytic conversion of urokinase. Thromb Res 1976; 09: 675-681
• 4 Gunzler WA, Steffens GJ, Ottins F, Buse G, Flohe L. Structural relationship between human high and low molecular mass urokinase. Hoppe Seylers Z Physiol Chem 1982; 363: 133-141
• 5 Fletcher AD, Alkjaersig N, Sherry S, Genton E, Hirsh J, and Bachmann F. The development of urokinase as a thrombolytic agent. Maintenance of a sustained thrombolytic state in man by its intravenous injection. J Lab Clin Med 1965; 64: 713-731
• 6 Sherry S. Therapeutic thrombolysis: Past, present and future. Thrombosis and Urokinase . pp 1-9 Paoletti R, and Sherry S. (Eds) Academic Press; NY: 1977
• 7 Stambaugh RL, Alexander MR. Therapeutic use of thrombolytic agents. Am J Hosp Pharm 1981; 38: 817-824
• 8 Kohler G, Howe SC, Milstein C. Fusion between immunoglobulinsecreting and nonsecreting myeloma cell lines. Eur J Immunol 1976; 06: 292-295
• 9 Lemhardt W, Andersson J, Coutinho A, Melchers F. Cloning of murine transformed cell lines in suspension culture with efficiencies near 100%. Exp Cell Res 1978; 111: 309-316
• 10 Goding JW. Conjugation of antibodies with fluorochromes: Modifications to the standard methods. J Immunol Methods 1976; 13: 215-226
• 11 Engrail E, Perlman P. Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G. Immunochem 1971; 08: 871
• 12 Holmberg L, Bladh B, Astedt B. Purification of urokinase by affinity chromatography. Biochim Biophys Acta 1976; 445: 215-222
• 13 Soria J, Soria C, Samama M. A plasminogen assay using a chromogenic substrate in clinical work and in thrombolysis studies. 3^rdInt Conf on Syn Fibr Thromb Agents. 1976: 28
• 14 Vetterlein D, Bell TE, Young PL, Roblin R. Immunological quantitation and immunoadsorption of urokinase-like plasminogen activators secreted by human cells. J Biol Chem 1980; 255: 3665-3672
• 15 Wray W, Boulikas T, Wray VP, Hancock R. Silver staining of proteins in polyacrylamide gels. Anal Biochem 1981; 118: 197-203
• 16 Lesuk A, Terminiello L, Traver JH. Crystalline urokinase: Some properties. Science 1965; 147: 880-882
• 17 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
• 18 Bollen A, Glineur C, Deleuve G, Loriau R, Herzog A. Expression in Escherischia coliof urokinase antigenic determinants. Biochem Biophys Res Commun 1981; 103: 391-401
• 19 Samama M, Cazenave B, Otero AM. Urokinase I and II activity. Thromb Haemostas 1979; 40: 578-580
• 20 Murano G, Aronson D, Williams L, Brown L. The inhibition of high and low molecular weight urokinase in plasma. Blood 1980; 55: 430-436